Eton Pharmaceuticals, Inc. Cash Flow Statement
ETON|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Eton Pharmaceuticals, Inc. generated $7M in operating cash flow and $7M in free cash flow in FY2025. Free cash flow margin was 21.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$936.0K | -$9.0M | -$2.0M | -$28.0M | -$18.3M | -$12.7M | -$7.2M |
| Depreciation & Amortization | $901.0K | $1.8M | $462.0K | $347.0K | $283.0K | $63.0K | $13.0K |
| Operating Cash Flow | $6.8M | $4.8M | -$4.7M | -$22.3M | -$18.0M | -$8.1M | -$4.7M |
| Capital Expenditures | $0 | $38.0K | $9.0K | $50.0K | $1.1M | $236.0K | $130.0K |
| Free Cash Flow | $6.8M | $4.8M | -$4.7M | -$22.4M | -$19.1M | -$8.4M | -$4.8M |
| FCF Margin | 21.5% | 22.5% | -21.7% | -57425.6% | -1993.9% | -873.9% | -969.6% |